SAN DIEGO, April 15 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals, Inc. (Nasdaq: SGXP) presented abstract #4844 at the 2008 Annual Meeting of the American Association for Cancer Research (AACR) in San Diego. The poster entitled "SGX523, a potent and exquisitely selective inhibitor of the HGF receptor tyrosine kinase (MET), inhibits growth of human glioblastoma tumors in a mouse model," was presented in the afternoon poster session entitled Small Molecule Kinase Inhibitors 1 in Exhibit Hall B-F.
SGX's MET program comprises potent, selective ATP-competitive MET inhibitors, from which a number of drug-like compounds have been identified. The first development candidate, SGX523, demonstrated potent anti-tumor activity when dosed orally in various mouse models of human cancer including glioblastoma, gastric cancer and lung cancer. SGX's second development candidate, SGX126, is structurally distinct and may possess several advantages over SGX523, including the potential for a lower human dose.
"We are continuing to progress SGX126 towards IND submission, while evaluating additional follow-on compounds for our MET program," said Mike Grey, the CEO of SGX Pharmaceuticals.
About SGX Pharmaceuticals
SGX Pharmaceuticals, Inc. is a biotechnology company focused on the
discovery, development and commercialization of novel, targeted
therapeutics directed at addressing unmet medical needs in oncology. Our
drug development programs target the MET receptor tyrosine kinase, an
enzyme implicated in a broad array of cancers, and the BCR-ABL tyrosine
kinase enzyme for the treatment of Chronic Myelogenous Leukemia, or CML.
Our drug discovery activities are focused on a portfolio of other protein
and enzyme targets that have been imp
|SOURCE SGX Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved